{"prompt": "['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 31 of 169', 'In total, 17 clinical trials have been conducted with tralokinumab, with phase 3 development', 'ongoing in asthma and AD. Other clinical trials with tralokinumab have been conducted in', 'subjects with ulcerative colitis, idiopathic pulmonary fibrosis, and in healthy subjects. Further', \"information on these trials can be found in the current Investigator's Brochure.\", 'In a phase 2b trial (D2213C00001), adults with moderate-to-severe AD on a background of', 'mild to moderate TCS, were treated with 3 different regimens of tralokinumab (45 mg every', 'second week [Q2W], 150 mg Q2W, or 300 mg Q2W) or placebo to evaluate the safety and', 'efficacy over a treatment period of 12 weeks. The primary endpoints were change from', 'baseline in Eczema Area and Severity Index (EASI) at Week 12 and the percentage of', 'subjects achieving IGA response of 0 (clear) or 1 (almost clear) at Week 12. Secondary', 'endpoints included change from baseline in EASI and Scoring Atopic Dermatitis (SCORAD)', 'scores, the percentage of subjects achieving at least 50% reduction from baseline in EASI and', 'SCORAD scores (EASI50 and SCORAD50). In the overall intent-to-treat phase 2b', 'population, an improvement in EASI score at Week 12 was seen in the tralokinumab 300 mg', 'Q2W group versus placebo. 26% of subjects achieved an IGA of 0 or 1 in the tralokinumab', '300 mg Q2W group versus 12% in the placebo group. The most commonly reported causally', 'related treatment-emergent adverse event was upper respiratory tract infection (6 [3.9%]', 'subjects in the combined tralokinumab group (45 mg, 150 mg, and 300 mg) and 2 [3.9%]', 'subjects in the placebo group).', 'In total, more than 2,343 subjects have been treated with tralokinumab (cut-off date:', '18-Aug-2017) based on actual exposure data from any completed clinical trials and the', 'enrolment/randomisation schemes for ongoing trials. The safety of all doses studied so far has', 'been with an acceptable benefit-risk profile and no major safety concerns have been', 'identified. Possible risks associated with use of tralokinumab are summarised in Section 5.5.', '5.3 Trial rationale', 'The purpose of this phase 3 trial is to provide evidence of the efficacy and safety of', 'tralokinumab monotherapy in the treatment of subjects with moderate-to-severe AD', 'inadequately controlled with topical therapies. Such subjects would be candidates for', 'systemic therapy.', 'The primary objective of this trial is to demonstrate that tralokinumab provides more effective', 'control of the skin manifestations of AD than placebo. The trial will evaluate the percentage', 'of subjects achieving IGA response of 0 (clear) or 1 (almost clear) and the percentage of', 'subjects achieving at least 75% reduction in EASI score (EASI75) at Week 16, with', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 32 of 169', 'secondary endpoints addressing symptom scores and extent of AD (SCORAD), itch severity,', 'and health-related quality of life (HQoL) measures related to AD.', 'As AD is a chronic disease requiring long-term treatment, it is also relevant to evaluate the', 'efficacy of tralokinumab as maintenance treatment. After the 16-week initial treatment period,', 'the trial will evaluate 2 different treatment options for maintenance therapy (300 mg Q2W and', '300 mg every 4 weeks [Q4W]).', 'As an exploratory component, the present trial will also investigate whether subjects who', 'have elevated levels of biomarkers of IL-13 may be more likely to respond to an IL-13', 'neutralising therapy. Periostin and dipeptidyl peptidase 4 (DPP4) were identified as key', 'markers of IL-13 mediated activation in the phase 2b trial (D2213C00001). In a post-hoc', 'analysis of trial D2213C00001, subjects with baseline serum DPP4 or periostin levels above', 'the median were seen to derive greater benefit from tralokinumab. Further exploratory', 'analyses of these biomarkers will be conducted so as to identify sub-populations where', 'prospective testing may be conducted in future clinical trials.', 'The trial will further characterise the benefit-risk profile of the drug and understand how best', 'to position tralokinumab in the AD treatment pathway.', '5.4 Justification for dose', 'The selected dose for the initial treatment period in trial is subcutaneously administered', '300 mg tralokinumab Q2W. All subjects randomised to receive treatment with tralokinumab', 'will get an initial loading dose of 600 mg on Day 0 (baseline). The administration of the', 'loading dose of tralokinumab will allow systemic concentrations to reach steady-state faster,', 'and potentially reduce the time to onset of clinical effect. The serum concentrations of', 'tralokinumab after the 600 mg loading dose will not exceed the serum tralokinumab', 'concentrations at steady state for the 300 mg Q2W.', 'The tralokinumab 300 mg Q2W dose was chosen based on the results of the phase 2b trial in', 'subjects with moderate-to-severe AD (trial D2213C00001) described in Section 5.2. The', 'subjects were treated with 3 different fixed dose regimens of tralokinumab (45, 150, or', '300 mg Q2W) or placebo to evaluate safety and efficacy over a treatment period of 12 weeks.', 'In the overall intention-to-treat phase 2b population, a statistically significant improvement in', 'EASI change from baseline at Week 12 was observed in the tralokinumab 300 mg group', 'versus placebo; however, formal statistical significance was not demonstrated for the', 'co-primary endpoint IGA. The key secondary and exploratory endpoint results from', 'trial D2213C00001 also support the selection of the tralokinumab Q2W 300 mg dose for', 'eDoc-00631888 - Version 4.0']\n\n###\n\n", "completion": "END"}